title: Plasmid pUDK-HGF encoding human hepatocyte growth factor gene attenuates gentamicin-induced kidney injury in rats.
abstract: The clinical application of gentamicin has been limited by its nephrotoxicity, which is characterized by kidney injury, interstitial fibrosis and progressive renal impairment. In this paper, we examine effects of plasmid pUDK-HGF which encodes the human hepatocyte growth factor (HGF) gene on gentamicin-induced renal injury in rats. The kidney injury was intentionally induced by injecting gentamicin intraperitoneally. On the third day after last gentamicin treatment, pUDK-HGF was injected into the left kidney tissue only once via a sterile back incision. At day 30 after gentamicin treatment, RI, Scr, BUN, 24 h-UTP and apoptotic cell death were determined. Tubulointerstitial injury and the renal interstitial vessel regeneration were evaluated by histological scoring. pUDK-HGF treatment significantly improved the renal function with decreasing RI, Scr and BUN. 24 h-UTP also presented ameliorating trend compared to the control group with kidney injury. pUDK-HGF treatment significantly decreased the score of tubulointerstitial injury and enhanced angiogenesis, also prevented kidney cells from apoptosis. The tubulointerstitial injury was significantly reduced in the pUDK-HGF injected left kidney and right kidney also showed some improvements. Our results showed that pUDK-HGF may become a novel therapeutic agent for kidney injury and renal fibrosis.
authors.affiliation: Chinese PLA General Hospital & Chinese PLA Postgraduate Medical School, Beijing 100853, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Chen
authors.forename: Zhi
authors.initials: Z
authors.lastname: Chen
authors.forename: Hanbin
authors.initials: H
authors.lastname: Wang
authors.forename: Xishan
authors.initials: X
authors.lastname: Xiong
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Liu
authors.forename: Chunsheng
authors.initials: C
authors.lastname: Hu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Han
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Lu
authors.forename: Zuze
authors.initials: Z
authors.lastname: Wu
authors.forename: Qinglin
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D017209:Apoptosis / Q000235:genetics; D005355:Fibrosis / Q000235:genetics / Q000517:prevention & control; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005839:Gentamicins / Q000633:toxicity*; D017228:Hepatocyte Growth Factor / Q000008:administration & dosage / Q000235:genetics*; D006801:Humans; D020287:In Situ Nick-End Labeling; D007677:Kidney Function Tests; D008297:Male; D008845:Microinjections; D010957:Plasmids; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D017228:Hepatocyte Growth Factor